Phase I BLASST-3 Trial

Summary

The aim of this research is to see whether using a drug that blocks a protein called FGFR (fibroblast growth factor receptor) prior to surgery is safe and effective in patients with bladder cancer that have mutations in FGFR3 or FGFR2 and who cannot receive chemotherapy with cisplatin prior to surgery The name of the study drug involved in this study is: \- Infigratinib

Timeline

Start

2021-12-23

Primary completion

2022-12

Completion

2023-12

Drugs

Indications